<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237808</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 15-10</org_study_id>
    <nct_id>NCT01237808</nct_id>
  </id_info>
  <brief_title>Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation</brief_title>
  <official_title>Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, Phase-III, two-arm, open-label, multi-center study in adult patients
      with AML and NPM1 mutation ineligible for intensive chemotherapy.

      Sample size: 144 patients

      Investigator's sites: 50-55 sites in Germany and Austria (2-10 patients per trial site are
      expected to be included into the trial)

      Estimated treatment duration of an individual patient: 8 months (Follow-Up period per patient
      will last additional 2 years)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years and 8 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Complete remission</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse</measure>
    <time_frame>2 years and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of death in complete remission</measure>
    <time_frame>2 years and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>2 years and 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early deaths (ED)/hypoplastic deaths (HD)</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, frequency, severity, timing and relatedness of adverse events (AEs) and laboratory abnormalities observed during different treatment cycles</measure>
    <time_frame>8 months</time_frame>
    <description>adverse events graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection after each treatment cycle</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of neutropenia after each treatment cycle</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of thrombocytopenia after each treatment cycle</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization after each treatment cycle</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years and 8 months</time_frame>
    <description>assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics according to Messerer et al.33</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).</description>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans retinoic acid (ATRA)</intervention_name>
    <description>in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.</description>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of acute myeloid leukemia according to the World
             Health Organization (WHO) classification (including de novo AML, t-AML and s-AML)

          -  Presence of NPM1 mutation as assessed in one of the central AMLSG reference
             laboratories.

          -  Age &gt; 60 years. There is no upper age limit.

          -  No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis if
             needed for up to 10 days during the diagnostic screening phase.

          -  Signed written informed consent

          -  Men must give their informed consent that they do not father a baby and must use a
             latex condom during any sexual contact with women of childbearing potential, even if
             they have undergone a successful vasectomy. (while on therapy and for 3 month after
             the last dose of chemotherapy)

          -  WHO performance status ≤ 3

          -  Patients not eligible for intensive chemotherapy according to at least one of the
             following criteria

               -  HCT-CI Score &gt;2

               -  Patient's decision

               -  age ≥ 75 years

        Exclusion Criteria:

        The presence of any of the following will exclude a patient from study enrollment:

          -  All other AML subtypes, in particular those AML with other recurrent genetic changes
             (according to WHO 2008):

               -  AML with t(8;21)(q22;q22); RUNX1-RUNX1T1

               -  AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11

               -  AML with t(15;17)(q22;q12); PML-RARA (or other translocations involving RARA)

               -  AML with t(9;11)(p22;q23); MLLT3-MLL (or other translocations involving MLL)

               -  AML with t(6;9)(p23;q34); DEK-NUP214

               -  AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1

          -  No consent for registration, storage and processing of the individual
             disease-characteristics and course as well as information of the family physician and
             all other treating physicians about study participation

          -  Bleeding disorder independent of leukemia

          -  Uncontrolled infection

          -  Known positive for HIV, HBV or HCV

          -  Organ insufficiency (creatinine &gt;1.5x upper normal serum level; bilirubin, AST or ALP
             &gt;2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV;
             severe obstructive or restrictive ventilation disorder)

          -  Severe neurological or psychiatric disorder interfering with ability of giving an
             informed consent

          -  Patients with a &quot;currently active&quot; second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a &quot;currently active&quot; malignancy if they
             have completed therapy and are considered by their physician to be at less than 30%
             risk of relapse within one year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Döhner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Ulm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ubbo-Emmius Klinik Aurich</name>
      <address>
        <city>Aurich</city>
        <zip>26603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Evangelischs Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Osthessen GmbH</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelm- Anton- Hospital gGmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Department III, Hospital of Hannover-Siloah</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I, University Hospital of Saarland</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interial Medicine /Hematology and Oncology, Caritas Hospital Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brueder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas-Klinik St. Theresia</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinikal Cetner of Stuttgart, Center of Oncology</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center II - Hematology/Oncology, Clinical Center Villingen-Schwenningen</name>
      <address>
        <city>Villingen - Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Hartmut Doehner</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>NPM1 Mutation</keyword>
  <keyword>elderly patients (&gt;60 years)</keyword>
  <keyword>unfit for intensive chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

